Smnumry We investigated the association between human papillomavirus (HPV) infection and p53 gene mutation in 47 primary uterine cervical cancers. HPV DNA sequences were present in 43 cancers (91.5%), and one of these cancers contained a p53 gene mutation. In addition, one of the remaining four HPV-negative cancers also contained a p53 gene mutation. As a result, p53 inactivation corresponded to the development of 44 of the primary uterine cervical cancers studied (93.6%). We obtained both primary and recurrent tumours from four cases. In two of these cases, the HPV genomes that were present in an episomal state in the primary tumours were observed to have disappeared in the recurrent tumours. One of these recurrent tumours also contained a p53 gene mutation, which suggested the possibility that p53 inactivation was September 1994 mutations could exist in other genes that interact with p53 or downstream of p53 and thus result in an identical physiological defect within the cell. Third, mutations in other genes, which are totally unrelated to p53, could occur in some cancers, resulting in a transformation process that is qualititatively different from HPV-mediated carcinogenesis. Thus, the present study was undertaken to define the molecular mechanism associated with HPV-negative cancer development.
Uterine cervical cancer is the most common genital malignancy, and a strong association with human papillomaviruses (HPVs) has been suggested (zur Hausen, 1987) . More than 65 different types of HPVs have been described. A subgroup of these viruses, including HPV types 16, 18, 31, 33, 52b and 58,  has been aetiologically implicated in cervical cell carcinogenesis (Fujinaga et al., 1991) because they are found in a high percentage of these cancers and because benign lesions, with which these viruses are usually associated, are considered to be precursors for malignant progression. Only part of the HPV genome, encoding the E6 and E7 proteins, is consistently retained and expressed in cancer cells. The coordinated expression of E6 and E7 has been shown to contribute to the transformation of rodent cells and the immortalisation of primary human keratinocytes (Bedell et al., 1989; Muinger et al., 1989; Barbosa et al., 1991) . One important function of the E6 oncoprotein is its ability to form a complex with the cellular p53 protein (Werness et al., 1990) , resulting in an ubiquitin-dependent degradation of the latter protein. Likewise, the E7 oncoprotein also forms a complex with the cell-encoded retinoblastoma protein (pRb) (Dyson et al., 1989) .
Mutations in the p53 gene are frequently observed in a wide vanrety of human malignancies (Hollstein et al., 1991) . It is thus conceivable that an abrogation of p53 gene functions could be implicated in the aetiology of cancers. Such p53 gene mutations have also been documented in cervical cancers and their cell lines. Only HPV-negative cervical cancers carry p53 mutations , an observation compatible with the assumption that the abrogation of the p53 gene functions is caused either by binding with the HPV E6-encoded protein or by a mutation associated with cervical cell carcinogenesis (Crook et al., 1991; . However, this hypothesis still remains inconclusive because the p53 inactivation may not be obligatory for a few HPV-negative cancers (Fujita et al., 1992 September 1994 mutations could exist in other genes that interact with p53 or downstream of p53 and thus result in an identical physiological defect within the cell. Third, mutations in other genes, which are totally unrelated to p53, could occur in some cancers, resulting in a transformation process that is qualititatively different from HPV-mediated carcinogenesis. Thus, the present study was undertaken to define the molecular mechanism associated with HPV-negative cancer development.
The polymerase chain reaction (PCR) and subsequent restriction enzyme typing are sufficiently sensitive to detect a subgroup of HPVs associated with cervical cancer. Both a sense primer, pU-lM, that is homologous to a region in the E6 open reading frame (ORF) and an antisense primer, pU-2R, that is homologous to a region in the E7 ORF were used for amplification. This method is also useful in identifying potentially new HPV types (Fujinaga et al., 1991) . Southern blot hybridisation in conjunction with polymerase chain reaction (PCR) was able to detect lo-5 to 106 copies of the HPV genome per cell, which was sufficient to determine the presence of HPVs (Roman and Fife, 1989) . We thus studied the frequency of HPV infection in 51 cervical cancers that involved both primary and recurrent tumours, and found four primary and two recurrent tumours that were HPV negative. The p53 gene mutation was recognised in 1 of the 45 HPV-positive tumours and in two of six HPV-negative tumours. The HPV genomes that were present as episomes in two primary cancers were observed to have disappeared in the recurrent tumours, and thus suggested the possible route of HPV-negative cancer development.
The disappearance of the HPV genome was followed by the appearance of a new p53 mutation in one of these two recurrent tumours. These findings might thus imply both p53 inactivation in the initiation of cervical cell carcinogenesis and the maintenance of transformed properties even if the frequency of p53 mutation was low in HPV-negative cancers.
The closest analogue to the interaction between E6 and p53 in cervical cancers is provided by the murine double minute 2 (MDM2) genes and p53 in sarcomas. An MDM2 gene product which binds to p53 has been shown to be amplified in a subset of sarcomas (Oliner et al., 1992 (Goelz et al.. 1985) .
Detection and tiping of HPV DNA The detection and typing of HPV DNA were performed using the polymerase chain reaction (PCR) as previously described (Fujinaga et al.. 1991 Cloning and sequencing Fragment F from codon 262 to codon 331 of the p53 gene which showed a mobility shift in the PCR-SSCP analysis was sequenced to confirm and localise any point mutations.
Since the primers used for the PCR-SSCP analysis had no extraneous nucleotides including any restriction of the enzyme-cut site. new primers, which had extraneous nucleotides including EcoRI and HindIII sites, where used for PCR in fragment F (Fl, 5'-CGAATTCTGAGTAGTGGT-AATCT-3'; F2, 5'-CCCAAGCTTTAGTACCTGAAGGGT-3'). PCR products were purified, digested with EcoRI and HindlII. and ligated into the EcoRI and HindIII sites of pUC18 plasmid. Sequencing was performed by the dideoxy sequencing reaction with BcaBEST DNA polymerase (TaKaRa), using fluorescein isothiocyanate (FITC)-labelled primers (FITC primer M4, 5'-CGCCAGGGTTT`TCCCAGTCAC-GAC-3'; FITC primer RV-M. 5'-GAGCGGATAACAATT-TCACACAGG-3'; TaKaRa). (Oliner et al., 1992) (MI, 5'-GTGGAATCTAGTFTITGCCCCTT-3'; M2, 5'-CTAGGGGAAATAAGTTAGCAC-3'). As a reference for the assessment of MDM2 gene amplification, the primers for PCR of phenylalanine hydroxylase (PAH) gene, which was also located on chromosome 12q, were designed to produce the DNA fragment (213 bp) which spanned exon 7 to part of intron 7 of PAH DNA sequence (Dworniczak et al.. 1990 ) (AP237, 5'-CCCAAACCTCATCTT`-GCAGCA-3'; AP333, 5'-CTTGCACTGGT-TTCCGCCTC-3'). Two oligonucleotide probes were synthesised by a Cyclone Plus DNA synthesiser (MilliGen Biosearch, Burlington, MA, USA) and were then used for hybridisation. The 50 bp MDM2 probe spanned nucleotides 1591 -1640 of the published MDM2 cDNA sequence (5'-AATCTAGTTTGCCCCTTAATGCCATTGA-ACCTTGTGTGATTTGTCAAGGT-3'). The 50 bp PAH probe spanned nucleotides 932-981 of the published PAH cDNA sequence (Kwok et al., 1985) (5'-GCACTGGTlTTCC-GCCTCCGACCTGTGGCTGGCCTGCTTTCCTCTCGG-GAT-3'). The signal of the MDM2 probe was then compared with that of the PAH probe. A 50 ng aliquot of DNA was subjected to PCR. One cycle of PCR consisted of denaturation (95°C for I mmn), primer annealing (55'C for 2 mmn), and extension (72°C for 2 min), for 25 cycles (Asakawa et al., 1992) . The PCR products were electrophoresed on 1.5% agarose gel. The procedures of denaturing, neutralisation, transferring, prehybridisation, hybridisation and washing were all performed as described above. The signals were also quantitated on a BAS1000, Bio-imaging Analyzer (Fujix).
Results
Pathology Table II) .
The detection of a p53 gene mutation in primary-cancers Cervical cancer DNAs were subjected to PCR-mediated amplification of exons 2-11, which covered the entire coding region of the p53 gene. The amplified fragments were analy- (Table II) . HPV genomes with more than 1.0 x 10-5 copies per cell could be detected by this method. Two-dimensional gel electrophoresis and Southern blot hybridisation using either HPV type 16 or 18 DNA as a probe clearly disclosed that the HPV DNA was present in both cancer cells in an episomal state (Figure 2 ). The HPV DNA types which were recognised in both primary and recurrent tumours were identical in the remaining cases, 45 and 47 (Table II) .
PCR-SSCP and sequencing of the p53 gene documented that the recurrent tumour of case 46 contained a CGT to TGT transversion of codon 273, which resulted in a substitution of Cys for Arg. A mutated allele alone was demonstrated at this site [ Figure 1 , case 46 (recurrence)]. However, no mobility shifts could be recognised in either case 44 with primary and recurrent cancers or in case 46 with primary cancer by a repeated analysis of SSCP and the sequencing of fragment F disclosed a wild-type nucleotide sequence.
p53 protein expression
Immunohistochemical staining using the anti-p53 mouse monoclonal antibody DO-7 was performed on 47 primary cervical cancer samples to demonstrate further the association between cervical cancer development and p53 inactivation. Both a normal cervical tissue specimen, which was not immunoreactive. and an endometrial cancer specimen, which was immunoreactive, were also subjected to staining as negative and positive controls respectively. The cancer cell nuclei of 12 samples showed a positive reaction (25%) even when the nuclei of the remaining 35 samples were immunonegative (75%). Case 10 alone showed the intense staining that was analogous to that of the positive control. The remaining 11 cases showed rather weak staining localised in the nuclei (Figure 3) (Soussi et al.. 1987 ). This might not be associated with the loss of the ability to be targeted for degradation by an E6 oncoprotein.
In the present study. three missense point mutations, which give rise to altered p53 proteins, were documented at amino acid residues 269. 273 and 292. Eleven of 12 mutations that are involved in the present three cases as well as the previously described nine cases (Paquette et al.. 1993) were clustered between amino acid residues 130 and 290.
which are highly conserved among several different species (Soussi et al.. 1987) . The results are consistent with the compiled data that described the position of point mutations in the human p53 gene from various malignancies (Hollstein et al.. 1991) . and thus suggest the importance of this conserved region for cervical cell carcinogenesis. A normal allele was present in addition to a mutated allele in case 10 even when only mutated alleles were observed in the remaining two cases. It remains to be clarified whether the results of case 10 indicate a heterozygous state or whether the presence of either normal tissue or inflammatory cells within the tumour sample is responsible for the apparent heterozygosity.
